We are live on ! Find out more
PASG icon

Passage Bio
PASG

43 hedge funds and large institutions have $32M invested in Passage Bio in 2024 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 7 increasing their positions, 11 reducing their positions, and 9 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

0.36% less ownership

Funds ownership: 3.62% → 3.27% (-0.36%)

10% less funds holding

Funds holding: 48 → 43 (-5)

36% less repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 11

41% less capital invested

Capital invested by funds: $54.4M → $32M (-$22.4M)

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

Holders
43
Holders Change
-5
Holders Change %
-10.42%
% of All Funds
0.62%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
4
Increased
7
Reduced
11
Closed
9
Calls
$7K
Puts
–
Net Calls
+$7K
Net Calls Change
-$40K

Top Buyers

1
VPC
Vestal Point Capital
New York
+$1.9M
2
LCM
Lynx1 Capital Management
Puerto Rico
+$259K
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$57.3K
4
TRCT
Tower Research Capital (TRC)
New York
+$16.1K
5
AI
Acuitas Investments
Washington
+$3.08K

Top Sellers

1
VVM
Versant Venture Management
California
-$1.14M
2
Two Sigma Advisers
Two Sigma Advisers
New York
-$283K
3
PFCS
Pale Fire Capital SE
Czech Republic
-$191K
4
Millennium Management
Millennium Management
New York
-$140K
5
BlackRock
BlackRock
New York
-$128K
Name Holding Trade Value Shares
Change 		Change in
Stake
CAM
26
Cresset Asset Management
Illinois
$18.8K – – –
HighTower Advisors
27
HighTower Advisors
Illinois
$17K -$294 -12 -1%
Fidelity Investments
28
Fidelity Investments
Massachusetts
$16.7K -$24 -1 -0.1%
XT
29
XTX Topco
Cayman Islands
$13.5K -$31.7K -1,296 -60%
Morgan Stanley
30
Morgan Stanley
New York
$10.7K -$489 -20 -3%
TRCT
31
Tower Research Capital (TRC)
New York
$10.5K +$16.1K +658 +32,900%
Barclays
32
Barclays
United Kingdom
$10.4K – – –
Royal Bank of Canada
33
Royal Bank of Canada
Ontario, Canada
$1K +$245 +10 +40%
UBS Group
34
UBS Group
Switzerland
$910 +$1.4K +57 New
Federated Hermes
35
Federated Hermes
Pennsylvania
$622 – – –
RhumbLine Advisers
36
RhumbLine Advisers
Massachusetts
$621 – – –
GRP
37
Global Retirement Partners
California
$318 +$489 +20 New
Bank of America
38
Bank of America
North Carolina
$291 +$440 +18 New
JP Morgan Chase
39
JP Morgan Chase
New York
$217 – – –
LI
40
LRI Investments
Florida
$179 – – –
HI
41
Harbour Investments
Wisconsin
$48 +$73 +3 New
Group One Trading
42
Group One Trading
Illinois
$37 – – –
Qube Research & Technologies (QRT)
43
Qube Research & Technologies (QRT)
United Kingdom
$4 – – –
Two Sigma Advisers
44
Two Sigma Advisers
New York
– -$283K -10,480 Closed
PFCS
45
Pale Fire Capital SE
Czech Republic
– -$191K -7,072 Closed
VF
46
Virtu Financial
New York
– -$34K -1,271 Closed
Marshall Wace
47
Marshall Wace
United Kingdom
– -$29.7K -1,100 Closed
CSS
48
Cubist Systematic Strategies
Connecticut
– -$15.2K -565 Closed
Citigroup
49
Citigroup
New York
– -$5.36K -198 Closed
Wells Fargo
50
Wells Fargo
California
– -$417 -15 Closed
1
2
3

PASG Hedge Fund Activity: Q2 2024 in Review

43 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q2 2024, worth a combined $32M — down 41% from $54.4M a quarter earlier.

Sellers outnumbered buyers: 9 funds closed out of PASG and 4 opened new positions — a net loss of 5 holders — while 11 trimmed existing stakes and 7 added.

The largest buyer was Vestal Point Capital, adding an estimated $1.9M. The largest seller was Versant Venture Management, cutting an estimated $1.14M.

  • 43 institutional investors held Passage Bio (PASG) as of Q2 2024, down from 48 in Q1 2024.
  • Funds reported $32M of Passage Bio stock for Q2 2024, down 41% quarter-over-quarter.
  • 4 funds opened new Passage Bio positions in Q2 2024 and 9 closed out, a net change of -5 holders.
  • The largest Passage Bio buyer in Q2 2024 was Vestal Point Capital, an estimated $1.9M added.
  • The largest Passage Bio seller in Q2 2024 was Versant Venture Management, an estimated $1.14M sold.

Based on aggregated 13F filings for Q2 2024.